Back to Search
Start Over
Medication use evaluation of the financial and clinical implications of ixazomib compared to bortezomib in the outpatient setting.
- Source :
-
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Mar; Vol. 27 (2), pp. 279-282. Date of Electronic Publication: 2020 Apr 11. - Publication Year :
- 2021
-
Abstract
- In the past decade, several new therapies have been approved for use in multiple myeloma, including the novel oral agent, ixazomib. Ixazomib, like bortezomib and carfilzomib, is a proteasome inhibitor, a class of agents that are a mainstay of treating multiple myeloma in both the frontline and relapsed settings. Ixazomib is administered orally and offers many potential advantages over the subcutaneous or intravenous administration of bortezomib. In this single-center, retrospective medication use evaluation, adult patients with multiple myeloma receiving either ixazomib or bortezomib in the outpatient setting were assessed to evaluate financial implications and tolerability. A total of 28 patients were included. The total wholesale acquisition cost for one cycle of ixazomib was $9942, and $6412 for bortezomib. Average reimbursement per cycle was $9205 for ixazomib and $5664 for bortezomib. Secondarily, the incidence of interruption in therapy was evaluated. Ixazomib was associated with a slightly higher incidence of interruption compared to bortezomib, 42.9% and 35.7%, respectively. It is notable that ixazomib has similar drug reimbursement rates to bortezomib, but slightly higher rates of interruption in therapy. In conclusion, if tolerable for the patient, ixazomib may offer a financially acceptable alternative for the treatment of multiple myeloma.
- Subjects :
- Administration, Oral
Adult
Aged
Aged, 80 and over
Ambulatory Care
Antineoplastic Agents administration & dosage
Antineoplastic Agents therapeutic use
Boron Compounds administration & dosage
Boron Compounds therapeutic use
Bortezomib administration & dosage
Bortezomib therapeutic use
Drug Costs
Female
Glycine administration & dosage
Glycine economics
Glycine therapeutic use
Humans
Injections, Subcutaneous
Insurance, Health, Reimbursement
Male
Middle Aged
Retrospective Studies
Antineoplastic Agents economics
Boron Compounds economics
Bortezomib economics
Glycine analogs & derivatives
Multiple Myeloma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1477-092X
- Volume :
- 27
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Publication Type :
- Academic Journal
- Accession number :
- 32279598
- Full Text :
- https://doi.org/10.1177/1078155220915963